Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank
May 14, 2024 4:12 PM EDTDeutsche Bank analyst James Shin lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $10.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "We're updating our STRO model for 1Q24 results, maintaining our Buy rating and lowering our price target to... More
Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO)
May 14, 2024 8:25 AM EDTWedbush analyst David Nierengarten reiterated an Outperform rating and $8.00 price target on Sutro Biopharma (NASDAQ: STRO)
The analyst comments "STRO reported 1Q24 earnings. The company continues to advance lead asset luvelta (FolR-targeted ADC) through multiple clinical studies. Part 1 of the registration-directed REFRaME-01 study in... More
